chrisvoncsefalvay/vaers-outcomes huggingface dataset:
He received his first dose back on 18Feb2021 then, tested positive for Covid; He received his first dose back on 18Feb2021 then, tested positive for Covid; This is a spontaneous report from a contactable consumer (reporting for himself). A 76-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 18Feb2021 (Batch/Lot number was not reported) as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced he received his first dose back on 18Feb2021 then, tested positive for COVID. The patient was treated "with and infusion". The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Lots consciousness for a minute Convulsions during the lost of consciousness bad cramps, intense chills, strong headache,  lost of appetite for a week, gastritis, and digestion issues.
Headache from approximately 1300 to 2000. I took naproxen  at 1600 which did not help headache.  Fell asleep at 2000.  Headache gone next morning.
10 minutes post vaccine, employee reported headache, quickly progressing to very severe headache, diaphoresis, vertigo, clouded cognition, feeling "disconnected"
Experienced some pain in my left side; I passed a urinary clot like a blood clot; It could be a urinary tract infection; I just passed the blood clot; felt really bad like he had no energy and slept on and off for 10 hours; felt really bad like he had no energy and slept on and off for 10 hours; felt really bad like he had no energy and slept on and off for 10 hours; I passed a urinary clot like a blood clot; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 62-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration, administered in Right shoulder on 15Apr2021 (at the age of 62 years) (Batch/Lot Number: EU00162) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included High Blood Pressure from 2010 to an unknown date. The Concomitant medications were not reported. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 on 20Mar2021 (at the age of 62 years) for covid-19 immunisation. Patient received the second dose of the Pfizer BioNTech Covid-19 vaccine on 15Apr2021, on 22Apr2021 he experienced pain in his left side and had no energy. This morning he passed a blood clot in his urine. He did not have any symptoms before, he was not sure if this is something that you have previously observed or heard maybe there is something in the past. He knew there are some issues with the vaccines like people were getting blood clots (further clarification unknown). Also, he was not sure if it was urinary clot, I was not sure if I was late, but it was just coincidental that it was after a week he got my shot. Patient stated, he guesses like he was in bed all day yesterday and today (not specified), he felt better but he just passed the blood clot, so he would say it was persisting. Stated, I was treating it now as a UTI infection until I find out otherwise, no such medications that he was taking. Stated yesterday, 22Apr2021, he experienced pain on his left side; felt really bad like he had no energy and slept on and off for 10 hours. He was reaching out to Pfizer to see if this has occurred with other people. The patient received the treatment for the event I passed a urinary clot like a blood clot. The clinical outcome of the event was unknown at the time of report.  No follow-up attempts are possible. No further information is expected.
when she received her second dose it also hurt a lot; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (when she received her second dose it also hurt a lot) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     The patient's past medical history included No adverse event. Concurrent medical conditions included No adverse event and No adverse event.    On 11-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (when she received her second dose it also hurt a lot). At the time of the report, VACCINATION SITE PAIN (when she received her second dose it also hurt a lot) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered VACCINATION SITE PAIN (when she received her second dose it also hurt a lot) to be not applicable.    Treatment information were not provided.   Reporter did not allow further contact
Dose 1 on 10-FEB-2021 and Dose 2 on 14-JUN-2021; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 10-FEB-2021 and Dose 2 on 14-JUN-2021) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 10-FEB-2021 and Dose 2 on 14-JUN-2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 10-FEB-2021 and Dose 2 on 14-JUN-2021) outcome was unknown. No concomitant medications were reported. No treatment medications were reported. This case was linked to MOD-2022-580789, MOD-2022-580794 (Patient Link).
hives all over my body started 10 days after the vaccination.  Not sure if it is related but i thought i should report this
CLIENT RECEIVED MODERNA FORMULATION AT 17YO. MODERNA IS APPROVES FOR AGES 18 AND ABOVE.
I felt like I had a mild flu after receiving the vaccine for about a day. I tested positive for COVID-19 in 08/2022. I contacted my doctor, and we decided that I do not take Paxlovid.  I had a headache, sore throat and a cough. I took over the counter medication to help with my symptoms. I had headaches for about a month after having COVID-19. I do not have a history of having headaches and I will have one or two every month.  My asthma seems to be more aggravated since having COVID-19. I am using my inhaler more than usual since COVID-19.
Pt. reports- "tightness of chest", palm sized area of slight, diffuse swelling, reddened. Pt. took self admin. with BENADRYL. No medical treatment or dx tests required. Fever 101.
Patient received both vaccines on the same day and one in each arm. The next morning patient had swelling over entire face and eyes. Says no throat/tongue swelling but had a scratchy throat.
3 1/2 in x 1 1/2in slightly erythemic, fading, non-tender area to L thigh at injection site.
Weakness in both lower limbs; Could not stand up; Hurts in both thighs, hip joints and knee joints.; Hurts in both thighs, hip joints and knee joints.; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (Weakness in both lower limbs), LIMB DISCOMFORT (Could not stand up), PAIN IN EXTREMITY (Hurts in both thighs, hip joints and knee joints.) and ARTHRALGIA (Hurts in both thighs, hip joints and knee joints.) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included Blood pressure pill for an unknown indication.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2021, the patient experienced MUSCULAR WEAKNESS (Weakness in both lower limbs), LIMB DISCOMFORT (Could not stand up), PAIN IN EXTREMITY (Hurts in both thighs, hip joints and knee joints.) and ARTHRALGIA (Hurts in both thighs, hip joints and knee joints.). At the time of the report, MUSCULAR WEAKNESS (Weakness in both lower limbs), LIMB DISCOMFORT (Could not stand up), PAIN IN EXTREMITY (Hurts in both thighs, hip joints and knee joints.) and ARTHRALGIA (Hurts in both thighs, hip joints and knee joints.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.
Bloody diaper, vomiting, weakness, fever, etc. Diagnosed with intussusception. Rotateq was determined to be the cause. Was initially treated at one hospital, then transferred by ambulance to another hospital.
mom reports pt became agitated, w/crying & screaming early, evening through the noc & subsided mid-day 13AUG95; pt lt thigh became hard, red & sore-mom noticed in the evening w/sxs subsiding in 24hrs; No contact w/MD;
Itching from head to toe; Her tongue was very dry about 20 minutes; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching from head to toe) and TONGUE DRY (Her tongue was very dry about 20 minutes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.     On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced PRURITUS (Itching from head to toe). On an unknown date, the patient experienced TONGUE DRY (Her tongue was very dry about 20 minutes). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, PRURITUS (Itching from head to toe) and TONGUE DRY (Her tongue was very dry about 20 minutes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant Concomitant medications were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Feb-2021 and was forwarded to Moderna on 23-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching from head to toe) and TONGUE DRY (Her tongue was very dry about 20 minutes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History Information was reported.     On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced PRURITUS (Itching from head to toe). On an unknown date, the patient experienced TONGUE DRY (Her tongue was very dry about 20 minutes). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, PRURITUS (Itching from head to toe) and TONGUE DRY (Her tongue was very dry about 20 minutes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant Concomitant medications were reported.
Hepatitis A; Drug Ineffective. This case was reported by a nurse and described the occurrence of a lack of effect in a 70 year old female patient who received hepatitis A vaccine inactivated (Havrix) for prophylaxis. The patient's medical history, concurrent conditions, and concurrent medications were not reported. On 15 April 1997, the patient received the first dose of Havrix. (lot VHA530B6). On 24 Octover 1997, the patient received the second dose of Havrix (lot VHA549A6). Approximately five years later, on 03 February 2003, the patient experienced "severe" headache, nocturnal fevers, decreased appetite, and malaise which persisted "off and on for two weeks." The patient sought medical attention from her physician. On 17 March 2003, hepatitis A IgM as "reactive". The patient was diagnosed with an acute hepatitis A infection. On 30 March 2003 the events resolved. The nurse considered the events to be unrelated to vaccination with Havrix.
Patient states that her arm was swollen and had a "small knot" at immunization site. She took ALEVE and applied ice pack to affected area and now her arm is much better. Patient also mentioned that she has suffered a fall since she received immunization.
Second dose of RabAvert was not administered by the schedule; Case reference number US-BN-2022-002301 is a spontaneous case report initially received on 08-Sep-2022 from a health care professional via Communication (reference number: USBAV22-1313) and concerns a 22-year-old female patient born in 1999.  The patient's relevant medical history and concomitant medications were not reported.  On 22-Aug-2022, the patient was vaccinated with first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP) (PCEC); batch number: unknown) administered intramuscularly at a dose reported as 1ml, at unknown anatomical site for pre-exposure to rabies.   It was reported that second dose of RabAvert was not administered by the schedule (explicitly coded as 'Missed dose').  At the time of this report, it was unknown if the patient experienced any adverse event.  Additional information received on 08-Sep-2022 included local case ID.; Reporter's Comments: A 22-year-old female patient born in 1999, was not administered by the schedule with the second dose of RabAvert which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event. The patient's relevant medical history and concomitant medications were not reported. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 22-year-old female patient born in 1999, was not administered by the schedule with the second dose of RabAvert which is considered as missed dose. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event. The patient's relevant medical history and concomitant medications were not reported. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Blood Glucose continues to be around 300 / patients glucose started to increase to 372; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE INCREASED (Blood Glucose continues to be around 300 / patients glucose started to increase to 372) in a 71-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS716813) for COVID-19 prophylaxis.     No previous Covid-19 infection.  Previously administered products included for Product used for unknown indication: Shingles Vaccine. Past adverse reactions to the above products included No adverse event with Shingles Vaccine. Concurrent medical conditions included Diabetes.    On 13-Dec-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 14-Dec-2022,  after starting , the patient experienced BLOOD GLUCOSE INCREASED (Blood Glucose continues to be around 300 / patients glucose started to increase to 372). At the time of the report, BLOOD GLUCOSE INCREASED (Blood Glucose continues to be around 300 / patients glucose started to increase to 372) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Dec-2022, Blood glucose: started to increase to 372.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.   Patient received her first Moderna Covid-19 vaccine on 11-February-2021 lot number 004M20A Expiration date is not known. Patient received the vaccine in her left arm. No adverse reactions. Patient received her second Moderna Covid-19 vaccine on 12-March-2021 lot number 023M20A Expiration date is not known. Patient received the vaccine in her left arm no adverse reactions. Patient received her first Moderna Covid-19 vaccine booster dose on 27-October-2021 lot number 048C21A Expiration date is not known. Patient received the vaccine in her left arm no adverse reactions.   No treatment information was provided.
Patient presented with with weakness and difficulty easting/driinking. Fully vaccinated and positive for COVID.
Pt. is a 72y.o. year old female with a history of COPD - 02 dependent, CHF, CKD, DM, HTN, recent PE receiving anticoagulation with Eliquis, prior left above ankle amputation presenting from her ECF with altered mental status, and hypoxia. The pt is currently arousable and will intermittently respond to questions with nodding or shaking her head - appears to respond appropriately, but otherwise non-verbal. History taken from review of the chart as well as discussion with her daughter who visits her at the ECF 5-7 times a week). Review of immunization record reveals prior documented receipt of Moderna vaccine 5/4 and 6/1/2021. Daughter also states her mother had COVID in April of this year (pos test). Negative SARS NAA here in June. At arrival of EMS pts 02 sat 81% breathing room air (normally on 4L NC per notes on chart, but daughter adamantly states her mother is not on supplemental O2).  At arrival to ER 02 sat 82% on 6L NC, vitals and T95.6 rectal. Placed on NRB with improvement in sat. Initial lab revealed a Hgb of 3.3, WBC 19.8, plt 245K, K 7.8, CO2 11 with AG 19, PT 28.6, lactic acid 6.2, normal transaminases and bili levels, BNP 991. Procal 0.39. UA with 3-5 RBC, >50 WBC and 3+ bacteriuria. SARS CoV2 (+) by NAA.  CXR with "Persistent low lung volumes with scattered airspace opacities and small bilateral pleural effusions which are better appreciated on CT chest 8/7/2021". CT chest revealed "Bilateral airspace disease and streaky atelectatic changes of the lung bases," CT abd/pelvis with "large rectal fecaloma, intervally increased from prior (now measuring 10.2 cm) with findings of early stercoral colitis," and hepatic steatosis. CT head neg for acute pathology.  Blood and urine were obtained for culture, and the pt was started on therapy with cefepime, metronidazole and vancomycin. She has received PRBC, and a RIJ Quinton was placed and HD initiated. Dexamethasone 10 mg IV was initiated.  At present she is maintaining an 02 sat of 100% on 2L NC, resolved hypothermia with current temp 99.3 bladder, HYPERtensive. Lab now reveals a significant increase in her transaminases to ~2700 with a normal bili, with elevated PT/INR.  ID is consulted regarding "covid +".
Local 3-4 in area of red, heated, tender, swelling at injection area. Self resolving.
INCREASED FATIGUE, HEADACHE, CHILLS, FEVER, LOSS OF SMELL/TASTE, ALL OVER PAIN (JOINT,BONES, MUSCLES, SKIN) FEELS LIKE IM 90 ALMOST CRIPPLING, DONT HAVE TO DO ANYTHING TO  BE IN PAIN, EXTREME TEMP VARIATION FREEZING COLD OR BURNING UP, BRUISING, SWELLING, RASH ITCHY/TINGLING/TIGHT SKIN, NUMBNESS, MILD VISION CHANGES, SOME SHORTNESS OF BREATH (UNSURE IF INCREASED OR SAME) WEIGHT CHANGES, INCREASED MALAISE.
Starting the day 1/19/21 after the injection she began experiencing severe back and midsection pain around the rib cage along with nausea and vomiting.
COVID Test Positive/treatment of COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID Test Positive/treatment of COVID-19) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form and dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID Test Positive/treatment of COVID-19). At the time of the report, COVID-19 (COVID Test Positive/treatment of COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: (Positive) Positive.     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       No concomitant medications were reported.   Patient started to get symptoms again and tested positive for COVID again. vaccine LOT number provided 041J21A.  No treatment medication was reported.
The symptoms happened while in the waiting room waiting the 15 minutes they tell you to wait sitting. I got very loud ringing in my ears, I felt very weak and lightheaded, had cold sweats, shortness of breath, chills, fast heart beat.
got shingles 5 months after receiving 2nd dose of shingrix/ suspected Vaccination failure; got shingles 5 months after receiving 2nd dose of shingrix; This case was reported by a pharmacist and described the occurrence of suspected vaccination failure in a 62-year-old female patient who received Herpes zoster (Shingrix) (batch number 5KM49, expiry date 26th November 2020) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) (batch number XG52X, expiry date 28th November 2020) and (batch number 5km, expiry date 26th November 2020) for prophylaxis.   On 19th October 2020, the patient received the 2nd dose of Shingrix. On 31st July 2020, the patient received the 1st dose of Shingrix. On 19th October 2020, the dose was an unknown dose. On an unknown date, 5 months after receiving Shingrix and between 7 and 8 months after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were provided as follows: Five months after receiving 2nd dose of Shingrix, the patient experienced shingles. The reporter wanted to know why it happened and if she could be revaccinated. This case was considered as suspected vaccination failure since the details regarding laboratory test confirming shingles were unknown. The reporter consented to follow up.